Drug Type Small molecule drug |
Synonyms 1-(2-(Biphenyl-4-yl)ethyl)-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine, SR 57667, SR 57667B + [2] |
Target |
Action stimulants |
Mechanism NGFB stimulants(Beta-nerve growth factor stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC26H24F3N |
InChIKeyCNEWKIDCGDXBDE-UHFFFAOYSA-N |
CAS Registry188396-77-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | Canada | 01 Mar 2004 | |
Alzheimer Disease | Phase 2 | Denmark | 01 Mar 2004 | |
Alzheimer Disease | Phase 2 | Finland | 01 Mar 2004 | |
Alzheimer Disease | Phase 2 | France | 01 Mar 2004 | |
Alzheimer Disease | Phase 2 | Germany | 01 Mar 2004 | |
Alzheimer Disease | Phase 2 | South Africa | 01 Mar 2004 | |
Alzheimer Disease | Phase 2 | Sweden | 01 Mar 2004 | |
Parkinson Disease | Phase 2 | Austria | 01 Jul 2003 | |
Parkinson Disease | Phase 2 | Canada | 01 Jul 2003 | |
Parkinson Disease | Phase 2 | Denmark | 01 Jul 2003 |